J Korean Rheum Assoc.  2007 Sep;14(3):268-273. 10.4078/jkra.2007.14.3.268.

Successful Treatment of Interstitial Pneumonitis Induced by Leflunomide

Affiliations
  • 1Department of Internal Medicine, Eulji Universitiy Hospital, Korea.
  • 2Department of Internal Medicine, Chungnam National Univiersity College of Medicine, Daejeon, Korea.
  • 3Department of Internal Medicine, Masan Samsung Medical Center, Masan, Korea. ironeagle@nate.com

Abstract

Leflunomide is a disease-modifying antirheumatic drug that has been available in Korea since 2003. Leflunomide induced interstitial pneumonitis has been reported as an adverse effect in other countries but not in Korea. A 57-year-old woman was treated with leflunomide since she had been resistant to methotrexate, hydroxychloroquine and sulfasalazine. She developed high fever, dyspnea, and non-productive cough 3 months after the administration of leflunomide. She was diagnosed leflunomide-induced interstitial pneumonitis based on history, physical, laboratory, radiologic and pathologic findings. The patient was treated by prednisolone 1 mg/kg/day with cholestyramine 24 g/day, resulting in dramatic improvement. Here we report a case of leflunomide induced pneumonitis treated successfully with high dose steroid.

Keyword

Leflunomide; Interstitial pneumonitis; Rheumatoid arthritis

MeSH Terms

Arthritis, Rheumatoid
Cholestyramine Resin
Cough
Dyspnea
Female
Fever
Humans
Hydroxychloroquine
Korea
Lung Diseases, Interstitial*
Methotrexate
Middle Aged
Pneumonia
Prednisolone
Sulfasalazine
Cholestyramine Resin
Hydroxychloroquine
Methotrexate
Prednisolone
Sulfasalazine
Full Text Links
  • JKRA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr